Guardant Health Inc. (GH) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, GH scores 53 out of 100 with a letter grade of D+, labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 9/20 (ROIC -17.4%; FCF yield -0.94%), Whale 13F Flow at 18/20 (institutional accumulation and options positioning), Insider Conviction at 6/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9/20 (Beta 0.87; sector sensitivity), and Forensic Balance Sheet at 11/20 (Altman Z 5.44; Piotroski F 6/9; Debt/Equity 0.85). The score is therefore carried mainly by institutional positioning, while the cash-generation and insider pillars are weak. For a prospective investor, the upside driver cited in the data is the institutional flow pillar; the principal valuation tradeoff is that the cash-engine pillar is weak against a forward P/E of 19 and a price of 185.31 near the top of its 52-week range. The forensic pillar indicates a balance sheet the source data characterizes as moderately leveraged with a passing Piotroski profile, but this does not offset negative operating economics. This brief is analytical and educational, not personalized financial advice.

Per the SEC financials, revenue rose from $563.9M (FY 2023) to $982.0M (FY 2025) while operating losses persisted in each period. Market data reports a gross margin of 64.5%, an operating margin of -44.5%, and a net margin of -42.4%. ROIC is -17.4% and FCF yield is -0.94%. Per the Roarable RQD rating forensic pillar, the Altman Z-Score is 5.44 and the Piotroski F-Score is 6/9, with a Debt/Equity ratio of 0.85.

• Market wire (Yahoo! Finance Canada, Yahoo Finance Singapore): general market-action and institutional-positioning coverage; no specific event described in the summary text.
• Price action (TradingKey): a report headlined an 8.27% decline on Oct 6 with no further detail in the summary.
• Analyst commentary (Seeking Alpha, tagged CATALYST): headline states "Growth Remains Too Expensive, Reiterate Hold."
• Technical commentary (FXEmpire): headline references a breakout with an upside price path toward $250; summary is generic.
• Clinical/partnership item (Stock Titan): headline describes a blood test in Europe that may help identify patients who may benefit from AstraZeneca's breast cancer drug.

Risk watch items: the Seeking Alpha valuation headline and the reported October decline. Proprietary signals: none listed in the Butterfly Supply-Chain Graph. Per the Butterfly Supply-Chain Graph, supply chain is NONE with no butterfly links.

• What is the P/E (TTM) and EV/EBITDA, given that both are reported as not available in source data while forward P/E is 19?
• What specific drivers account for the FY 2023 debt of $3200.5M falling to $950.8M by FY 2025, and what is the company's debt maturity profile?
• What is the path to positive operating income given reported operating margin of -44.5%?
• Who are the institutional holders and insiders behind the Whale and Insider pillar scores, since the holders section is empty?
• What is the EPS for FY 2025, since the financials list EPS as N/A across all periods?